Systemic Absorption of Topically Administered Drugs

Compendium on Continuing Education for the Practicing Veterinarian

Volumn 22, Issue 7, 2000, Pages 649-656

  Mealey, Katrina ^a,b  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b Amer Coll of Vet Clin Pharmacol   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0346985095     PISSN: 01931903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Wepierre J, Marty JP: Percutaneous absorption of drugs. Trends Pharmacol Sci 1:23-26, 1979.
2. Guzzo CA, Lazarus GS, Werth VP: Dermatological pharmacology, in Hardman JG, Limbird LE (eds): Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York, McGraw-Hill, 1996, pp 1593-1616.
3. Banks WJ: Integumentary system, in Banks WJ (ed): Applied Veterinary Histology. Baltimore, Williams & Wilkins, 1986, pp 348-379.
4. Aungst BJ, Blake JA, Rogers NJ, Hussain MA: Transdermal oxymorphone formulation development and methods for evaluating flux and lag times for two skin permeation-enhancing vehicles. J Pharm Sci 79(12):1072-1076, 1990.
5. Lin S, Xing QF, Chien YW: Transdermal testosterone delivery: Comparison between scrotal and nonscrotal delivery systems. Pharm Dev Technol 4(3):405-414, 1999.
6. Steinstrasser I, Merkle HP: Dermal metabolism of topically applied drugs: Pathways and models reconsidered. Pharm Acta Helv 70(1):3-24, 1995.
7. Mealey KL, Boothe DM: Nephrotoxicity associated with topical administration of gentamicin in a cat. JAVMA 204(12):1919-1921, 1994.
8. Sudekum M, Poppenga RH, Raju N, Braselton WE: Pennyroyal oil toxicosis in a dog. JAVMA 200(6):817-818, 1992.
9. Zenoble RD, Kemppainen RJ: Adrenocortical suppression by topically applied corticosteroids in healthy dogs. JAVMA 191(6):685-688, 1987.
10. Dorman DC: Neurotoxic drugs in dogs and cats, in Bonagura JD (ed): Kirk's Current Veterinary Therapy of Small Animal Practice, XII. Philadelphia, WB Saunders Co, 1995, pp 1140-1145.
11. Hansen SR: Management of organophosphate and carbamate insecticide toxicoses, in Bonagura JD (ed): Kirk's Current Veterinary Therapy of Small Animal Practice, XII. Philadelphia, WB Saunders Co, 1995, pp 245-248.
12. Yagi S, Nakayama K, Kurosaki Y, et al: Factors determining drug residence in skin during transdermal absorption: Studies on beta-blocking agents. Biol Pharm Bull 21(11):1195-1201, 1998.
13. Regnier A: Ocular pharmacology and therapeutic modalities, in Gelatt KN (ed): Veterinary Ophthalmology. Philadelphia, Lea & Febiger, 1991, pp 162-194.
14. Van Ootegham MM: Formulations of ophthalmic solutions and suspensions: Problems and advantages, in Edman P (ed): Biopharmaceutics of Ocular Drug Delivery. Boca Raton, FL, CRC Press, 1993, pp 27-42.
15. Fraunfelder FT, Meyer SM: Systemic side effects from ophthalmic timolol and their prevention. J Ocular Pharm 3:177-184, 1987.
16. Pascoe PJ, Ilkiw JE, Stiles J, Smith EM: Arterial hypertension associated with topical ocular use of phenylephrine in dogs. JAVMA 205(11):1562-1564, 1994.
17. Glaze MB, Crawford MA, Nachreiner RF, et al: Ophthalmic corticosteroid therapy: Systemic effects in the dog. JAVMA 192(1):73-75, 1988.
18. Roberts SM, Lavach JD, Macy DW, Severin GA: Effect of ophthalmic prednisolone acetate on the canine adrenal gland and hepatic function. Am J Vet Res 45(9):1711-1714, 1984.
19. Hollingsworth SR, Canton DD, Ruyukmihci NC, Farver TR: Effect of topically administered atropine on tear production in dogs. JAVMA 200(10):1481-1484, 1992.
20. Bellot JL, Ali JL, Ruiz-Moreno JM, Artola A: Corneal concentration and systemic absorption of cyclosporin A following its topical application in the rabbit eye. Ophthalmic Res 24(6):351-356, 1992.
21. Svec AL, Strosberg AM: Therapeutic and systemic side effects of ocular β-adrenergic antagonists in anesthetized dogs. Invest Ophthalmol Vis Sci 27:401-405, 1986.
22. Brooks DE: Glaucoma in the dog and cat. Vet Clin North Am Small Anim Pract 20:775-798, 1990.
23. Muir WW: Pharmacology and pharmacokinetics of antiarrhythmic drugs, in Fox PR (ed): Canine and Feline Cardiology. New York, Churchill Livingstone, 1988, pp 309-333.
24. Everitt DE, Avorn J: Systemic effects of medications used to treat glaucoma. Ann Intern Med 112:120-124, 1990.
25. Rush JE: Emergency therapy and monitoring of heart failure, in Bonagura JD (ed): Kirk's Current Veterinary Therapy of Small Animal Practice, XII. Philadelphia, WB Saunders Co, 1995, pp 713-721.
26. Fernandez-de-Sevilla T, Alegre J, Vallespi T, et al: Adult pure red cell aplasia following topical ocular chloramphenicol. Br J Ophthalmol 74(10):640, 1990.
27. Jacob SW, Wood DC: Dimethyl sulfoxide (DMSO): Toxicology, pharmacology, and clinical experience. Am J Surg 114(3):414-426, 1967.
28. Gorog P, Kovacs IB: Antiarthritic and antithrombotic effects of topically applied dimethyl sulfoxide. Ann NY Acad Sci 243:91-97, 1975.
29. Van Heyningen R, Harding JJ: Some changes in the lens of the dimethylsulphoxide-fed rabbit. Exp Eye Res 14(2):91-98, 1972.
30. Heywood R: Drug-induced lenticular lesions in the dog. Br Vet J 127(7):301-303, 1971.
31. Rubin LF: Toxicity of dimethyl sulfoxide, alone and in combination. Ann NY Acad Sci 27:243:98-103, 1975.
32. Idson B: Percutaneous absorption. J Pharm Sci 64(6):901-924, 1975.
33. Chandrasekaran SK, Shaw JE: Factors influencing the percutaneous absorption of drugs. Curr Probl Dermatol 7:142-155, 1978.
34. Ghosh TK, Bagherian A: Development of a transdermal patch of methadone: In vitro evaluation across hairless mouse and human cadaver skin. Pharm Dev Technol 1(3):285-291, 1996.
35. Tsai JC, Guy RH, Thornfeldt CR, et al: Metabolic approaches to enhance transdermal drug delivery. 1. Effect of lipid synthesis inhibitors. J Pharm Sci 85(6):643-648, 1996.
36. Yellowlees P, Greenfield C, McIntyre N: Dimethylsulphoxide-induced toxicity. Lancet 2(2802):1004-1006, 1980.
37. O'Malley M: Clinical evaluation of pesticide exposure and poisonings. Lancet 349(9059):1161-1166, 1997.